据《新京报》5月6日报道，安徽阜阳一名患者因头晕接受刺五加注射液治疗后，出现意识模糊等症状， 最后经抢救无效死亡。 从开始输液到抢救无效死亡仅约2小时，目前患者家属已要求封存病历，进行尸检。阜阳市卫生健康 委、阜阳市中医医院同步启动事件调查，正在开展尸检，具体死亡原因等待调查。 此类中药注射液引发不良反应的案例并不鲜见。四川省药品不良反应监测中心此前的研究数据显示，刺 五加注射液近半数不良反应集中在用药后30分钟内，严重不良反应主要为过敏样反应、过敏性休克、哮 喘，甚至出现患者死亡等。 医药魔方统计数据显示，2023年刺五加注射液以6.14亿元的销售额位居中药注射液前列。 面对部分中药注射剂安全性争议，国家药监局近年频繁修订说明书。例如，炎琥宁注射剂已被标注"接 受本品治疗的患者有发生严重过敏反应的风险，包括过敏性休克，严重者可导致死亡"的黑框警示。 北京中医药大学卫生健康法治研究与创新转化中心主任邓勇告诉21世纪经济报道记者，中药注射剂是中 药现代化的一种探索形式，它在危急重症的治疗等方面有一定的作用和优势，如在一些感染性疾病、心 脑血管疾病的治疗中能发挥独特疗效。 "然而，其确实存在安全性隐患。不能因噎废 ...

截至本公告披露日，钱熙文先生未持有公司股份，不存在应当履行而未履行 的承诺事项。钱熙文先生在担任公司财务负责人期间恪尽职守、勤勉尽职，公司 董事会对其任职期间为公司做出的贡献表示衷心感谢。 股票代码：002750 股票简称：*ST 龙津 公告编号：2025-048 昆明龙津药业股份有限公司 关于财务负责人辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 昆明龙津药业股份有限公司（以下简称"公司"）董事会于 2025 年 4 月 30 日收到公司财务负责人钱熙文先生的书面辞职报告，钱熙文先生因个人原因辞任 公司财务负责人，辞职后不再担任公司及子公司任何职务，该辞职报告自送达公 司董事会之日起生效。 为保证公司财务工作的正常开展，在财务负责人空缺期间，暂由公司财务部 部长马榕女士代行职责。公司董事会将按照法定程序，尽快完成新任财务负责人 的聘任。 特此公告。 昆明龙津药业股份有限公司董事会 2025 年 4 月 30 日 1 ...

Core Viewpoint - ST Longjin is facing delisting due to a net profit loss in the recently disclosed 2024 annual report and revenue falling below 300 million, triggering delisting conditions [2][14]. Company Overview - Longjin Pharmaceutical was established in September 1996, focusing on the research, production, and sales of modern traditional Chinese medicine and high-end chemical generics [2]. - The company’s representative products include injection of Ligusticum Chuanxiong, injection of fibrinolytic enzyme, and injection of Bivalirudin, with Ligusticum Chuanxiong being the core product [2]. Stock Performance - Longjin Pharmaceutical was listed in 2015 during a bull market, with its stock price peaking at 135 yuan before experiencing a significant decline, dropping to around 6 yuan within two years [2]. - In 2019, the company invested 15 million yuan to acquire a 51% stake in Yunnan Muya Agricultural Technology Co., which focuses on large-scale industrial hemp cultivation, leading to a stock price surge from 5 yuan to 23.5 yuan in two months [4]. - The stock was heavily speculated upon due to the industrial hemp concept, achieving multiple trading halts in 2021, earning the title of the "first industrial hemp stock" [4]. Financial Performance - From 2021 to 2024, Longjin Pharmaceutical's revenue showed a drastic decline: 702.5 million, 123 million, 86.62 million, and 66.48 million respectively, with net profits of 3.093 million, -56.12 million, -70.94 million, and -41.44 million, indicating three consecutive years of losses [7]. - The company was placed under delisting risk warning by the Shenzhen Stock Exchange in the previous year due to a negative net profit and revenue below 100 million [8]. Recent Developments - Following the delisting risk warning, Longjin Pharmaceutical's stock faced a series of trading halts, with the price plummeting to around 1 yuan after multiple trading suspensions [9][11]. - Currently, there are nearly 30,000 shareholders, many of whom are stuck with high-priced shares and reluctant to sell [14]. Industry Context - The number of listed companies in A-shares has exceeded 5,000, with an increasing number of delistings each year, highlighting the importance of avoiding poorly performing stocks [16].

2025年4月29日，*ST龙津(002750.SZ)发布2025年一季报。 公司截至2025年3月31日，*ST龙津营业总收入为590.18万元，在已披露的同业公司中排名第71，较去年 同报告期营业总收入减少2048.67万元，同比较去年同期下降77.64%。截至2025年3月31日，*ST龙津归 母净利润为-407.99万元，在已披露的同业公司中排名第62。截至2025年3月31日，*ST龙津经营活动现 金净流入为-1284.91万元，在已披露的同业公司中排名第47，较去年同报告期经营活动现金净流入减少 808.48万元。 公司截至2025年3月31日，*ST龙津最新资产负债率为12.60%。 公司截至2025年3月31日，*ST龙津最新毛利率为64.50%，较去年同期毛利率减少4.62个百分点。截至 2025年3月31日，*ST龙津最新ROE为-0.88%，在已披露的同业公司中排名第64。 公司截至2025年3月31日，*ST龙津摊薄每股收益为-0.01元，在已披露的同业公司中排名第61。 公司截至2025年3月31日，*ST龙津最新总资产周转率为0.01次，在已披露的同业公司中排名第71，较去 年同期 ...

◎记者 祁豆豆 在退市新规实施后的首个年报季，新修订的组合类财务退市指标正式"亮剑"，将一批净利润亏损且营收 不足3亿元的主板公司精准"圈出"，充分揭示这些公司持续经营能力羸弱的风险，部分公司因此被实施 退市风险警示（*ST），还有多家*ST公司将直接退市。 据上海证券报记者统计，截至4月29日21时，触发组合类财务退市指标的主板公司共有48家。初步来 看，触发该指标的公司所属行业以社会服务、机械设备、纺织服饰居多。从公司基本面看，多家公司亏 损年份超过3年，且主营业务多次转型仍效果不佳，个别公司甚至面临财务类、规范类、重大违法强制 类等多重退市风险。 上海市君和律师事务所律师季凌昊向记者表示，针对主板公司的组合类财务退市指标精准识别"壳公 司"，将加速"劣币"出清，有助于引导资金流向盈利稳定、基本面良好的公司。同时，退市新规的威慑 力也会倒逼上市公司"提质增效"，让更多上市公司专注于可持续性的核心竞争力的构建。 收紧营业收入指标 多家主板公司"披星戴帽" 4月29日，艾艾精工发布2024年年报，因公司2024年度经审计的扣除非经常性损益前后的净利润均为负 值，且扣除与主营业务无关的业务收入和不具备商业实质的 ...

Summary of Key Points Core Viewpoints - The report highlights the ongoing trend of stock suspensions due to delisting risk warnings across multiple companies, indicating a potential downturn in market confidence and stability [2][3][4]. Company Listings - Several companies are scheduled for initial public offerings (IPOs) on April 29, 2025, including Tai Li Technology (301595) and Ze Run New Energy (301636), which may attract investor interest [1]. - The report notes the specific dates for various IPO-related activities, such as inquiry periods and fund unfreezing dates, which are crucial for market participants [1]. Stock Suspension Announcements - Numerous companies, including Guohua Network Security (000004) and Nanhua Biology (000504), have announced stock suspensions due to delisting risk warnings, reflecting a significant concern regarding their financial health [2][3]. - The report lists a total of 30 companies facing stock suspensions on April 29, 2025, due to various risk warnings, which may impact investor sentiment and trading volumes [2][3][4]. Special Suspensions - Companies like *ST Xu Lan (000040) and *ST Gong Zhi (000584) are highlighted for potential termination of listings, indicating severe financial distress and regulatory scrutiny [4][5]. - The report emphasizes the importance of monitoring these companies as their situations evolve, which could present both risks and opportunities for investors [4][5].

Financial Performance - The company's revenue for Q1 2025 was ¥5,901,760.59, a decrease of 77.64% compared to ¥26,388,422.34 in the same period last year[5] - The net profit attributable to shareholders was -¥4,079,872.65, showing an improvement of 9.17% from -¥4,491,776.72 year-on-year[5] - Total operating revenue for the current period is 5,901,760.59, a decrease of 77.7% compared to 26,388,422.34 in the previous period[19] - Net profit for the current period is -4,890,695.58, an improvement from -5,566,204.56 in the previous period[20] - Basic and diluted earnings per share for the current period are both -0.0102, slightly improved from -0.0112 in the previous period[21] Cash Flow and Assets - The net cash flow from operating activities was -¥12,849,141.89, a decline of 169.70% compared to -¥4,764,302.80 in the previous year[5] - Operating cash flow for the current period is -12,849,141.89, worsening from -4,764,302.80 in the previous period[22] - The company's cash and cash equivalents decreased from 261,742,130.25 CNY to 50,854,157.95 CNY, a decline of approximately 80.6%[15][16] - Cash and cash equivalents at the end of the period are 50,854,097.38, down from 129,653,249.19 in the previous period[23] - Total current assets decreased from 338,177,284.73 CNY to 311,106,917.55 CNY, a reduction of about 8%[16] - The total liabilities decreased from 80,185,043.61 CNY to 69,958,735.88 CNY, a decrease of approximately 12.5%[17] - The company's total assets decreased from 574,398,586.84 CNY to 555,151,183.53 CNY, a decline of about 3.4%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,091[11] - The largest shareholder, Kunming Qunxing Investment Co., Ltd., holds 39.40% of the shares, totaling 157,782,293 shares[11] Government Support and Subsidies - The company received government subsidies amounting to ¥846,338.40 during the reporting period[6] - Other income for the current period is 846,338.40, an increase from 677,867.89 in the previous period[20] Expenses and Costs - The company's sales expenses decreased by 83.84% to ¥2,796,905.35 due to the implementation of centralized procurement policies[9] - Total operating costs for the current period are 11,934,554.14, down 64.7% from 33,756,765.30 in the previous period[19] - Research and development expenses for the current period are 1,676,309.60, down from 1,992,368.82 in the previous period[19] Investment and Financial Assets - The company reported a significant increase in trading financial assets, which rose by 556.62% to ¥219,437,991.06[9] - The company’s investment income decreased by 95.55% to ¥29,110.89, attributed to cash management products not maturing[9] - Investment activities generated a net cash flow of -197,329,574.98, compared to -86,299,874.27 in the previous period[23] Risks and Challenges - The company has received a notice from the Shenzhen Stock Exchange regarding the potential termination of its stock listing due to negative profits and revenue below ¥300 million[4] - The core product, Longjin® injection of Lampflower extract, is expected to face risks of declining sales and revenue due to the national centralized procurement policy starting in April 2025[14] Asset Changes - The company's retained earnings decreased from 18,950,761.77 CNY to 14,870,889.12 CNY, a decline of approximately 21.4%[17] - The total equity attributable to the parent company decreased from 470,459,142.64 CNY to 464,319,475.03 CNY, a reduction of about 1.4%[17] - The company's intangible assets increased by 51.35% to ¥50,465,817.98 due to new drug production approvals[9]

Operating Overview - The total operating revenue of ST Longjin (002750) for 2024 was 66.48 million yuan, a year-on-year decrease of 23.25% [2] - The net profit attributable to shareholders was -41.44 million yuan, an increase of 41.58% year-on-year; the net profit after deducting non-recurring gains and losses was -50.46 million yuan, up 37.78% year-on-year [2] - Despite poor annual performance, the fourth quarter showed improvement with total operating revenue of 19.87 million yuan, a year-on-year increase of 27.65% [2] Profitability Analysis - The company's profitability improved in 2024, with a gross margin of 64.25%, an increase of 5.53% year-on-year [3] - The net profit margin was -70.66%, an increase of 27.36% year-on-year, indicating that the company remains in a loss position [3] Cost and Expense Analysis - Total sales, management, and financial expenses amounted to 66.58 million yuan, accounting for 100.15% of revenue, a decrease of 7.73% year-on-year [4] - The reduction in sales expenses was primarily due to the implementation of centralized procurement price linkage policies in non-centralized procurement provinces [4] Cash Flow Situation - The operating cash flow per share was -0.09 yuan, an increase of 12.8% year-on-year, indicating some improvement [5] - However, the average operating cash flow over the past three years relative to current liabilities was -78.8%, suggesting ongoing concerns regarding cash flow [5] Asset and Liability Situation - The company's cash and cash equivalents amounted to 262 million yuan, a year-on-year increase of 24.2%, indicating a healthy cash position [6] - Accounts receivable decreased by 27.86% year-on-year to 8.75 million yuan, reflecting improved collection [6] Development Prospects and Risks - The company has been deeply involved in the pharmaceutical manufacturing industry for many years, holding nearly 40 domestic and foreign invention patents [7] - However, the product structure remains single, with revenues from other chemical generic drugs being relatively small [7] - The company faces multiple risks, including industry policy changes, research and development innovation, management, and safety and environmental protection [7] Summary - Overall, ST Longjin showed some recovery in profitability in 2024, but the overall operating condition remains under significant pressure [8] - The company needs to further optimize its product structure, enhance market competitiveness, and strengthen cash flow management and risk prevention for sustainable development [8]

*ST嘉寓（300117）收到股票终止上市决定，*ST龙津（002750）收到终止上市事先告知书。 4月25日晚，深交所发布了《关于嘉寓控股股份公司股票终止上市的公告》，决定终止*ST嘉寓公司股票上市。 同日，*ST龙津发布公告称，收到深交所《终止上市事先告知书》，由于触及财务类退市，交易所拟决定终止公司股票上市交易。 *ST嘉寓即将退市 4月25日晚，*ST嘉寓公告称，公司当天收到深交所《关于嘉寓控股股份公司股票终止上市的决定》，深交所决定终止公司股票上市。 该终止上市决定显示，*ST嘉寓在2025年3月4日至2025年3月31日期间，连续20个交易日的股票收盘价均低于1元，触及深交所《创业板股票上市规则(2024 年修订)》第10.2.1条第一款第二项规定的股票终止上市情形。根据深交所《创业板股票上市规则(2024年修订)》第10.2.5条的规定以及深交所上市审核委员 会的审议意见，决定公司股票终止上市。 由于公司股票因触及交易类强制退市情形被终止上市，公司股票将不进入退市整理期，将于交易所作出终止上市决定后十五个交易日内摘牌。 事实上，早在4月1日，*ST嘉寓就已经收到终止上市事先告知书，公司股票也自4 ...

股票代码：002750 股票简称：*ST 龙津 公告编号：2025-046 昆明龙津药业股份有限公司 关于收到终止上市事先告知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 二、风险提示 1 根据《深圳证券交易所股票上市规则》及《关于退市公司进入退市板块挂牌 转让的实施办法》等有关规定，如果深圳证券交易所最终决定公司股票终止上市， 公司股票将转入全国股转公司代为管理的退市板块挂牌转让，涉及具体事项公司 将另行公告。 公司郑重提醒广大投资者，《证券时报》和深圳证券交易所网站 （www.szse.cn）为公司选定的信息披露媒体，公司所有信息均以在上述媒体披 露的信息为准。请广大投资者理性投资，注意风险。 三、备查文件 一、《终止上市事先告知书》的具体内容 昆明龙津药业股份有限公司（以下简称"公司"）2025 年 4 月 25 日收到深 圳证券交易所送达的《终止上市事先告知书》（公司部函[2025]第 193 号），具 体内容如下： "昆明龙津药业股份有限公司： 2024 年 5 月 6 日，因你公司 2023 年度经审计的净利润为负值且营业收入低 于 1 ...